Hercules Capital
Hercules Capital is a capital market company that lends to technology, life sciences, and sustainable technology companies.
Business Model:
Revenue: $294M
Employees: 51-200
Rankings
Detailed Hercules Capital Information
Geographic Data
Address: 400 Hamilton Avenue
City: Palo Alto
State: CA
Zip: 94301
Country: US
Financial Info
Stage:
Raised Last:
$7M
Raised Total:$7M
Social
Twitter
Linkedin
Crunchbase
Metrics
3,157,853Website Global Rank
5,147Website Monthly Traffic
Twitter Followers
Description
Hercules is the largest non-bank lender to venture capital-backed companies at all stages of development in a broadly diversified variety of technology, life sciences, and sustainable and renewable technology industries. With over a decade of experience in venture debt, Hercules is uniquely positioned to quickly create innovative financing solutions that perfectly fit within a company&s;s existing capital structure and map to its business objectives. Recognized as the industry leader, Hercules understands the flexibility these types of companies need and has the experience to work closely with them, even through challenging times, to help them reach critical milestones. Hercules&s; deep sector expertise, geographic presence and its strong capital base have made Hercules the lender of choice for more than 480 innovative companies.
Contact Phone:
+16502893060
Contact Email:
Hercules Capital went public on 5/4/2012 on the NYSE
Listed Exchange:
NYSE
IPO Date:
5/4/2012
Ticker Symbol:
HTGC
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 6/2013 | Rockwell Medical | Post-IPO Debt | 20M |
| 3/2006 | Compete, Inc. | Venture Round | 4M |
| 10/2020 | Bicycle Therapeutics | Debt Financing | 50M |
| 6/2005 | Labopharm | Debt Financing | 10M |
| 3/2021 | Humanigen | Post-IPO Debt | 80M |
| 10/2022 | Replimune Group | Post-IPO Debt | 200M |
| 4/2007 | Everyday Health Group | Debt Financing | 8M |
| 12/2014 | Dynavax Technologies | Debt Financing | 40M |
| 5/2018 | Asensus Surgical | Post-IPO Debt | 40M |
| 11/2007 | Zayo | Debt Financing | 85M |
| 9/2021 | Corium International | Debt Financing | 235M |
| 6/2017 | Concert Pharmaceuticals | Post-IPO Debt | 30M |
| 10/2008 | Blurb | Debt Financing | 2.5M |
| 7/2018 | Acacia Pharma | Debt Financing | 30M |
| 9/2021 | 3Gtms | Private Equity Round | 0 |
| 2/2015 | SparkPost | Debt Financing | 8M |
| 7/2007 | Purcell Systems | Venture Round | 15M |
| 7/2018 | Merrimack Pharmaceuticals | Post-IPO Debt | 25M |
| 11/2014 | nContact Surgical | Debt Financing | 20M |
| 1/2015 | MELA Sciences | Post-IPO Debt | 10M |
| 2/2019 | Urovant Sciences | Debt Financing | 100M |
| 4/2016 | FuelCell Energy | Post-IPO Debt | 25M |
| 7/2016 | Aprecia Pharmaceuticals | Debt Financing | 30M |
| 2/2010 | Propel Fuels | Debt Financing | 8M |
| 12/2014 | SOASTA | Debt Financing | 15M |
| 7/2014 | UniQure | Post-IPO Debt | 20M |
| 4/2007 | IKANO Communications | Post-IPO Debt | 22.5M |
| 11/2013 | Celsion | Post-IPO Debt | 20M |
| 3/2016 | Mast Therapeutics | Post-IPO Debt | 15M |
| 12/2007 | Shocking Technologies | Debt Financing | 4M |
| 3/2010 | Velocity Technology Solutions | Debt Financing | 25M |
| 10/2022 | Bright Machines | Debt Financing | 0 |
| 8/2022 | Provention Bio | Post-IPO Debt | 125M |
| 11/2012 | TransMedics | Venture Round | 36M |
| 3/2017 | 908 Devices | Debt Financing | - |
| 8/2020 | AVEO Oncology | Post-IPO Debt | 35M |
| 7/2013 | BioAmber | Post-IPO Debt | 25M |
| 12/2018 | Contentful | Series D | 33.5M |
| 8/2007 | Quartics | Venture Round | 7.5M |
| 2/2014 | ADMA Biologics | Post-IPO Debt | 15M |
| 9/2014 | ChromaDex | Post-IPO Debt | 5M |
| 1/2006 | Optovia Corporation | Debt Financing | 5M |
| 1/2011 | Anthera Pharmaceuticals | Post-IPO Debt | - |
| 10/2013 | Cleveland BioLabs | Post-IPO Debt | 10M |
| 10/2006 | IWatt | Venture Round | 7M |
| 1/2008 | Kadoink | Debt Financing | 2.5M |
| 4/2018 | Dashlane | Debt Financing | 10M |
| 4/2019 | Dashlane | Debt Financing | 30M |
| 11/2007 | WildTangent | Debt Financing | 20M |
| 6/2015 | Proterra | Series D | 55M |
| 1/2012 | Clustrix | Debt Financing | 4M |
| 5/2015 | ReachLocal | Post-IPO Debt | 25M |
| 8/2017 | BioQ Pharma | Debt Financing | - |
| 2/2017 | Sio Gene Therapies | Post-IPO Debt | 55M |
| 6/2010 | BuyerLink | Venture Round | 15M |
| 1/2006 | Simpler Networks | Debt Financing | 10M |
| 9/2007 | Crux Biomedical | Venture Round | 250k |
| 12/2005 | Atrenta | Venture Round | 10M |
| 11/2020 | Udacity | Debt Financing | 75M |
| 7/2017 | Sebacia | Debt Financing | 16M |
| 1/2015 | Cerulean Pharma | Post-IPO Debt | 26M |
| 5/2007 | Neosil | Debt Financing | 10M |
| 5/2006 | GameLogic | Debt Financing | 3M |
| 6/2012 | AMSC | Post-IPO Debt | 10M |
| 4/2014 | Alimera Sciences | Post-IPO Debt | 35M |
| 1/2015 | Bellicum Pharmaceuticals | Post-IPO Debt | - |
| 5/2021 | SCYNEXIS | Post-IPO Debt | 60M |
| 3/2005 | Omrix Biopharmaceuticals | Venture Round | 4.8M |
| 6/2013 | Anacor Pharmaceutical | Post-IPO Debt | 45M |
| 6/2005 | Sportvision | Debt Financing | 4M |
| 4/2007 | NuGEN Technologies | Debt Financing | 3M |
| 5/2014 | Medrobotics | Series E | 26M |
| 2/2006 | HighRoads | Debt Financing | 2.5M |
| 5/2015 | Machine Zone | Debt Financing | - |
| 8/2021 | Novelion Therapeutics | Post-IPO Debt | 50M |
| 8/2010 | Calera | Venture Round | 15M |
| 11/2006 | Elixir Pharmaceuticals | Debt Financing | 15M |
| 6/2014 | CareCloud Corporation | Debt Financing | 25.5M |
| 8/2006 | Agami System | Debt Financing | 11M |
| 4/2007 | Rubicon Technology | Post-IPO Debt | 16M |
| 12/2007 | hi5 | Debt Financing | 15M |
| 6/2022 | Akero Therapeutics | Post-IPO Debt | 0 |
| 9/2014 | Edge Therapeutics | Debt Financing | 10M |
| 3/2005 | Inxight Software | Debt Financing | 5M |
| 6/2016 | Plug Power | Post-IPO Debt | 70M |
| 1/2007 | Blurb | Debt Financing | 2.5M |
| 2/2016 | CytRx | Post-IPO Debt | 40M |
| 12/2013 | CTI BioPharma | Post-IPO Debt | 5M |
| 12/2018 | Nabriva Therapeutics | Post-IPO Debt | 75M |
| 4/2022 | Viridian Therapeutics | Post-IPO Debt | 0 |
| 4/2014 | JumpStart | Debt Financing | 13M |
| 3/2018 | Tricida | Debt Financing | 100M |
| 3/2013 | Medrobotics | Debt Financing | 10M |
| 3/2017 | Verastem Oncology | Post-IPO Debt | 25M |
| 5/2009 | E-Band Communications | Series C | - |
| 6/2022 | Geron | Post-IPO Debt | 0 |
| 4/2010 | PolyMedix | Post-IPO Equity | 14M |
| 4/2018 | RumbleON | Post-IPO Debt | 15M |
| 5/2021 | HiberCell | Debt Financing | 30M |
| 3/2016 | Quanterix | Series D | 46M |
| 12/2014 | MELA Sciences | Post-IPO Debt | 20M |
| 3/2019 | Constellation Pharmaceuticals | Post-IPO Debt | 40M |
| 10/2005 | Affinity Express | Venture Round | 3M |
| 4/2007 | Tectura | Debt Financing | 22M |
| 5/2010 | Chroma Therapeutics | Debt Financing | 15M |
| 11/2020 | CloudBolt | Debt Financing | 20M |
| 3/2018 | Metalysis | Venture Round | 16.9M |
| 12/2013 | Baxano Surgical | Post-IPO Debt | 15M |
| 12/2014 | ADMA Biologics | Post-IPO Debt | 5M |
| 1/2020 | ChemoCentryx | Post-IPO Debt | 100M |
| 6/2017 | Antares Pharma | Post-IPO Debt | 35M |
| 6/2012 | just.me Inc | Debt Financing | 1.5M |
| 10/2013 | InspireMD | Post-IPO Debt | 10M |
| 12/2020 | SingleStore | Series E | 0 |
| 7/2022 | Gritstone Bio | Post-IPO Debt | 80M |
| 6/2015 | Zosano Pharma | Post-IPO Debt | 15M |
| 5/2005 | WageWorks | Debt Financing | 20M |
| 2/2008 | Mode Media | Debt Financing | 20M |
| 7/2015 | Gynesonics | Venture Round | 43M |
| 7/2006 | BARRX Medical | Series C | 27.8M |
| 2/2015 | SparkPost | Series C | 27M |
| 10/2005 | AGEIA Technologies | Series C | 27.5M |
| 5/2020 | SingleStore | Debt Financing | 50M |
| 10/2011 | BrightSource Energy | Debt Financing | 35M |
| 10/2022 | Tricida | Post-IPO Debt | 125M |
| 11/2022 | Kura Oncology | Post-IPO Debt | 125M |
| 7/2006 | BabyUniverse, Inc. | Post-IPO Debt | 5M |
| 12/2013 | AcelRx Pharmaceuticals | Post-IPO Debt | 40M |
| 5/2010 | Alexza Pharmaceuticals | Post-IPO Debt | 15M |
| 6/2020 | G1 Therapeutics | Post-IPO Debt | 100M |
| 9/2021 | Phathom Pharmaceuticals | Post-IPO Debt | 200M |
| 8/2020 | UNITY Biotechnology | Post-IPO Debt | 80M |
| 1/2008 | Rise Broadband | Venture Round | 15M |
| 2/2020 | ZeroFOX | Series D | 74M |
| 7/2016 | Auris Medical | Post-IPO Debt | 12.5M |
| 7/2012 | Virident Systems | Venture Round | 5.7M |
| 10/2017 | Myovant Sciences | Post-IPO Debt | 40M |
| 6/2005 | Merrimack Pharmaceuticals | Debt Financing | 9M |
| 2/2015 | Agile Therapeutics | Post-IPO Debt | 25M |
| 10/2021 | Eloxx | Post-IPO Debt | 30M |
| 3/2007 | Memory Pharmaceuticals | Post-IPO Debt | 10M |
| 11/2012 | CapLinked | Series A | 0 |
| 1/2006 | Xillix | Debt Financing | 5.5M |
| 5/2010 | AVEO Oncology | Post-IPO Equity | 25M |
| 3/2019 | Aldeyra Therapeutics | Post-IPO Debt | 60M |
| 3/2009 | RazorGator | Debt Financing | 10M |
| 8/2005 | Adiana | Series D | 23M |
| 3/2012 | Alphabet Energy | Debt Financing | 2M |
| 8/2012 | Fortress Biotech | Post-IPO Debt | 15M |
| 12/2006 | Nexx Systems | Debt Financing | 10M |
| 12/2005 | Cradle Technologies | Series E | 0 |
| 7/2007 | SiCortex | Debt Financing | 10M |
| 6/2007 | Panacos Pharmaceuticals | Post-IPO Debt | 20M |
| 7/2007 | Prism Career Institute | Debt Financing | 3M |
| 5/2006 | OATSystems | Debt Financing | 6M |
| 8/2006 | NOVASYS MEDICAL | Debt Financing | 8M |
| 3/2013 | NeuralStem | Post-IPO Debt | 8M |
| 1/2018 | Intuity Medical | Venture Round | 0 |
| 8/2022 | Alladapt Immunotherapeutics | Debt Financing | 50M |
| 3/2019 | FuelCell Energy | Post-IPO Debt | - |
| 8/2015 | Modumetal | Venture Round | 33.5M |
| 3/2005 | RazorGator | Series A | 26M |
| 6/2014 | Nanotherapeutics | Debt Financing | 30M |
| 2/2015 | Message Systems | Debt Financing | 27M |
| 12/2012 | Comverge | Debt Financing | 34M |
| 4/2006 | Sirtris Pharmaceuticals | Debt Financing | - |
| 6/2016 | Flowonix | Debt Financing | 5M |
| 5/2018 | CloudPay | Equity | 25M |
| 11/2006 | Elixir Pharmaceuticals | Series C | 0 |
| 3/2007 | PSS Systems | Debt Financing | 5M |
| 2/2016 | Aria Systems | Series E | 0 |
| 2/2022 | Lucira Health | Post-IPO Debt | 80M |
| 7/2014 | SINTX Technologies | Post-IPO Debt | 0 |
| 1/2013 | ADMA Biologics | Debt Financing | 6M |
| 7/2022 | IVERIC bio | Post-IPO Debt | 250M |
| 11/2014 | Flowonix | Venture Round | 20M |
| 4/2016 | ClearObject | Series E | 0 |
| 3/2006 | Market Force Information | Debt Financing | 8M |
| 1/2019 | Mesoblast | Post-IPO Debt | 75M |
| 8/2022 | ATAI Life Sciences | Post-IPO Debt | 175M |
| 11/2012 | NuPathe | Post-IPO Debt | 8.5M |
| 8/2021 | Better Therapeutics | Debt Financing | 50M |
| 1/2023 | AmplifyBio | Debt Financing | 50M |
| 10/2007 | Diomed Holdings | Debt Financing | 10M |
| 12/2021 | Carwow | Debt Financing | 54.8M |
| 1/2006 | Acceleron Pharma | Debt Financing | 8M |
| 1/2018 | Gynesonics | Private Equity Round | 75M |
| 10/2014 | Gamma Medica | Series B | 0 |
| 2/2015 | Melinta Therapeutics | Post-IPO Debt | 30M |
| 1/2015 | Aspire Bariatrics, Inc. | Debt Financing | 12M |
| 6/2014 | Celator Pharmaceuticals | Debt Financing | 15M |
| 3/2006 | RazorGator | Series B | 22.8M |
| 12/2007 | E-Band Communications | Series B | 10M |
| 3/2007 | Transcept Pharmaceuticals | Series D | 40M |
| 5/2012 | kaleo | Debt Financing | 15M |
| 10/2021 | Locus Biosciences | Debt Financing | 25M |
| 1/2020 | Syndax Pharmaceuticals | Post-IPO Debt | 0 |
| 5/2022 | Madrigal Pharmaceuticals | Post-IPO Debt | 250M |
| 2/2022 | Esme Learning Solutions | Venture Round | 15M |
| 12/2005 | Guava Technologies | Debt Financing | 10M |
| 11/2022 | Phathom Pharmaceuticals | Post-IPO Debt | 40M |
| 1/2022 | TG Therapeutics | Post-IPO Debt | 70M |
| 2/2019 | TG Therapeutics | Post-IPO Debt | 60M |
| 10/2022 | Automation Anywhere | Debt Financing | 200M |
| 6/2015 | Proterra | Debt Financing | 25M |
| 11/2022 | Oak Street Health | Post-IPO Debt | 300M |
| 6/2005 | Sling Media | Debt Financing | 4M |
| 10/2006 | Atrenta | Venture Round | 0 |
| 12/2005 | Cornice | Series C | 97M |
| 11/2022 | Locus | Series F | 0 |
| 5/2007 | QuatRx Pharmaceuticals | Series E | 0 |
| 2/2023 | Skydio | Series E | 0 |
| 5/2007 | Intelliden | Series E | 10M |
| 12/2021 | NorthSea Therapeutics | Series C | 0 |
| 4/2014 | Neos Therapeutics | Debt Financing | 20M |
| 6/2022 | X4 Pharmaceuticals | Post-IPO Equity | 0 |
| 1/2019 | BridgeBio Pharma | Equity | 299.2M |
| 9/2016 | Druva | Series E | 51M |
| 12/2013 | ViewRay | Venture Round | 0 |
| 6/2009 | Kamada | Venture Round | 20M |
| 8/2016 | Mattersight | Post-IPO Debt | 30M |
| 3/2010 | InfoLogix | Venture Round | 3M |
| 7/2022 | IVERIC bio | Post-IPO Debt | 0 |
| 7/2022 | Gritstone Bio | Post-IPO Debt | 0 |
| 6/2022 | Geron | Post-IPO Debt | 0 |
| 6/2022 | X4 Pharmaceuticals | Post-IPO Equity | 0 |
| 6/2022 | Akero Therapeutics | Post-IPO Debt | 0 |
| 5/2022 | Madrigal Pharmaceuticals | Post-IPO Debt | 0 |
| 4/2022 | Viridian Therapeutics | Post-IPO Debt | 0 |
| 2/2022 | Esme Learning Solutions | Venture Round | 0 |
| 2/2022 | Lucira Health | Post-IPO Debt | 0 |
| 1/2022 | TG Therapeutics | Post-IPO Debt | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
